Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TradersChoice 2000 -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Jordan who wrote (581)	2/3/2000 10:59:00 AM
From: Dan Duchardt	Read Replies (1) \| Respond to of 604

Jeff, The LIPO news should have come to no surprise to people who follow the stock. I think it was overdone. This news was already built into the price. At $10 I would think it was a good deal; at $11 I'd want to see some more gain. LIPO does have other drugs in the marketplace. They are a profitable company with what most people believe is a valuable technology, even if this EVACET drug never flies. There is a pretty steady rumbling about someone buying them out if the stock does not rebound soon, but who knows about these things. I am far from an expert on biotechs, but given the renewed interest in the sector, and the profitability of this company, it seems a lot less risky than many. I am still long LIPO with some FEB calls written at 12_1/2 and 15. Looks like I'll get to write another round of calls in a couple of weeks. Eventually, I'll break even on this one. <g> Dan